At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
Moderately hypofractionated conformal radiation combined With S-1combination
Likely dose
Moderately hypofractionated conformal radiation combined With S-1 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Phase Ⅱ Study of S-1 Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Moderately hypofractionated conformal radiation combined With S-1 for Esophageal Squamous Cell Carcinoma. Completed, enrolled 58 participants across 1 site.
Detailed Summary
This Phase II randomized study is to determine the efficacy and toxicities of moderately hypofractionated conformal radiation combined With S-1 for esophageal squamous cell carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Squamous Cell Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedSep 2018
Primary CompletionJul 2022
TodayJul 2026
First PostedSep 6, 2018
Enrollment StartOct 1, 2017
Primary CompletionJul 30, 2022
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 7.8 years ago
Interventions
Moderately hypofractionated conformal radiation combined With S-1combination
All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.